Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-β-cyclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection

Abstract

Background Paclitaxel (PTX) solid lipid nanoparticles (SLNs) modified with 2-hydroxypropyl-β-cyclodextrin (HPCD) were evaluated for their ability to enhance PTX absorption and reduce the nephrotoxicity accompanying intravenous administration. Methods PTX-loaded SLNs (PS) and PTX-loaded SLNs modified using HPCD (PSC) were prepared by hot-melted sonication. The anticancer activity of PSC was evaluated in MCF-7 cells, and confocal microscopy was used to quantify the cellular uptake. The pharmacokinetic profiles of PTX released from PSC after intravenous administration were studied in rats. Furthermore, kidney toxicity was determined by measuring the kidney size and plasma creatinine level. Results PSC were successfully prepared by hot-melted sonication and had smaller diameters than PS. PSC exhibited improved anticancer activity and cellular uptake in MCF-7 cells. Furthermore, PSC showed higher bioavailability in rats after intravenous administration than PTX solution; however, no significant differences in kidney toxicity were observed. Conclusion Based on these results, PSC could be considered as a potential therapeutic PTX delivery system for breast cancer with low renal toxicity.

Paclitaxel-Loaded Core–Shell Magnetic Nanoparticles and Cold Atmospheric Plasma Inhibit Non-Small Cell Lung Cancer Growth

“…PTX stabilizes the microtubules by binding to the polymeric tubulin, thereby preventing tubulin breakdown, inhibiting mitosis, and inducing apoptosis in a variety of cancer cells. , However, the main limitations of using PTX include its poor water solubility (∼0.4 μg·mL –1 ), toxicity, and nonspecificity. , Nanoformulations developed with PTX show numerous advantages over current standard chemotherapy. For example, PTX-loaded solid lipid nanoparticles associated with 2-hydroxypropyl-β-cyclodextrin were able to enhance absorption and reduce PTX toxicity and drug resistance . In the present case, the new PTX preparations that could be used to enhance therapeutic effects still have great therapeutic significance.…”

“…For example, PTX-loaded solid lipid nanoparticles associated with 2-hydroxypropyl-β-cyclodextrin were able to enhance absorption and reduce PTX toxicity and drug resistance. 14 In the present case, the new PTX preparations that could be used to enhance therapeutic effects still have great therapeutic significance. Biodegradable polylactic-co-glycolic acid (PLGA) was selected as an excellent candidate by the FDA for human use because it is biodegradable, biocompatible, and does not show systemic cytotoxicity.…”

Lymphoma-targeted treatment using a folic acid-decorated vincristine-loaded drug delivery system

“…Free VCR, VCR/LPNs, and FA-VCR/LPNs (each contained 10 mg/kg of VCR) were intravenous injected via the tail vein, respectively. 26 Blood samples (300 µL) were collected at pre-determined times (0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24, 48, and 72 h) in polypropylene microcentrifuge tubes, centrifuged at 15,000 rpm for 5 minutes to isolate the plasma, and stored at −80°C and subsequently analyzed by HPLC using the method mentioned in the “Drug encapsulation and loading efficiency” section.…”

A multifunctional lipid nanoparticle for co-delivery of paclitaxel and curcumin for targeted delivery and enhanced cytotoxicity in multidrug resistant breast cancer cells

“…Considering the modulation of drug release to inhibit p-gp first, our group developed inclusion complex-loaded solid lipid nanoparticles (SLNs) that enabled to release p-gp inhibitor faster than anticancer drug [ 20 ]. SLNs have been used in wide range of properties owing to low toxicity and good potential in cosmetic, food and pharmaceutical fields [ 21 – 23 ].…”